MUSTANG BIO INC (MBIO) Stock Fundamental Analysis

NASDAQ:MBIO • US62818Q3020

0.8741 USD
-0.04 (-3.91%)
At close: Feb 13, 2026
0.8915 USD
+0.02 (+1.99%)
After Hours: 2/13/2026, 8:22:56 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MBIO. MBIO was compared to 521 industry peers in the Biotechnology industry. While MBIO seems to be doing ok healthwise, there are quite some concerns on its profitability. MBIO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year MBIO has reported negative net income.
  • In the past year MBIO has reported a negative cash flow from operations.
  • In the past 5 years MBIO always reported negative net income.
  • MBIO had a negative operating cash flow in each of the past 5 years.
MBIO Yearly Net Income VS EBIT VS OCF VS FCFMBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • MBIO has a better Return On Assets (-12.06%) than 82.73% of its industry peers.
  • MBIO's Return On Equity of -23.90% is amongst the best of the industry. MBIO outperforms 80.23% of its industry peers.
Industry RankSector Rank
ROA -12.06%
ROE -23.9%
ROIC N/A
ROA(3y)-182.96%
ROA(5y)-131.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MBIO Yearly ROA, ROE, ROICMBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MBIO Yearly Profit, Operating, Gross MarginsMBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • MBIO has less shares outstanding than it did 1 year ago.
  • MBIO has less shares outstanding than it did 5 years ago.
  • MBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MBIO Yearly Shares OutstandingMBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
MBIO Yearly Total Debt VS Total AssetsMBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -28.07, we must say that MBIO is in the distress zone and has some risk of bankruptcy.
  • MBIO has a Altman-Z score of -28.07. This is amonst the worse of the industry: MBIO underperforms 86.18% of its industry peers.
  • There is no outstanding debt for MBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.07
ROIC/WACCN/A
WACCN/A
MBIO Yearly LT Debt VS Equity VS FCFMBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • MBIO has a Current Ratio of 2.05. This indicates that MBIO is financially healthy and has no problem in meeting its short term obligations.
  • MBIO's Current ratio of 2.05 is on the low side compared to the rest of the industry. MBIO is outperformed by 75.43% of its industry peers.
  • A Quick Ratio of 2.05 indicates that MBIO has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.05, MBIO is not doing good in the industry: 73.51% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.05
Quick Ratio 2.05
MBIO Yearly Current Assets VS Current LiabilitesMBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • MBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.53%, which is quite impressive.
EPS 1Y (TTM)98.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, MBIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.53% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.62%
EPS Next 2Y39.11%
EPS Next 3Y25.28%
EPS Next 5Y15.53%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MBIO Yearly Revenue VS EstimatesMBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
MBIO Yearly EPS VS EstimatesMBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -200 -400 -600 -800

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MBIO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MBIO Price Earnings VS Forward Price EarningsMBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MBIO Per share dataMBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • MBIO's earnings are expected to grow with 25.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.11%
EPS Next 3Y25.28%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • MBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MUSTANG BIO INC

NASDAQ:MBIO (2/13/2026, 8:22:56 PM)

After market: 0.8915 +0.02 (+1.99%)

0.8741

-0.04 (-3.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)03-26
Inst Owners4.35%
Inst Owner Change50.48%
Ins Owners0.05%
Ins Owner Change41.3%
Market Cap6.38M
Revenue(TTM)N/A
Net Income(TTM)-2.33M
Analysts82.86
Price TargetN/A
Short Float %0.65%
Short Ratio0.49
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.65
P/tB 0.65
EV/EBITDA N/A
EPS(TTM)-1.26
EYN/A
EPS(NY)-2.02
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0
BVpS1.34
TBVpS1.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -12.06%
ROE -23.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-182.96%
ROA(5y)-131.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.05
Quick Ratio 2.05
Altman-Z -28.07
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)34.36%
Cap/Depr(5y)80.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.07%
EPS Next Y42.62%
EPS Next 2Y39.11%
EPS Next 3Y25.28%
EPS Next 5Y15.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y91.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.88%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y90.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y90.36%
OCF growth 3YN/A
OCF growth 5YN/A

MUSTANG BIO INC / MBIO FAQ

What is the ChartMill fundamental rating of MUSTANG BIO INC (MBIO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MBIO.


Can you provide the valuation status for MUSTANG BIO INC?

ChartMill assigns a valuation rating of 1 / 10 to MUSTANG BIO INC (MBIO). This can be considered as Overvalued.


Can you provide the profitability details for MUSTANG BIO INC?

MUSTANG BIO INC (MBIO) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for MBIO stock?

The Earnings per Share (EPS) of MUSTANG BIO INC (MBIO) is expected to grow by 42.62% in the next year.